CAR-T (Chimeric Antigen Receptor T-cell) therapies are a form of personalized immunotherapy primarily intended for the treatment of certain types of cancer, particularly hematological malignancies such as leukemias and lymphomas. In this therapy, a patient’s own immune cells are genetically modified to precisely recognize cancer cells and, once re-administered to the body, selectively eliminate them.
CAR-T therapies enable highly targeted treatment and are already an important component of modern oncology for patients in whom standard treatments have not been successful.
GaiaCell develops CAR-T cell therapies with a clear objective: to simplify manufacturing, shorten the time to clinical application, and increase control over key technological elements while maintaining clinical efficacy. Our approach addresses the limitations of existing CAR-T models and enables the development of solutions that are more adaptable, logistically feasible, and scalable in the long term.
Despite outstanding clinical achievements, CAR-T therapies remain constrained by several key challenges:
A particularly critical bottleneck is the lentiviral vector, a core component of CAR-T therapies. Centralized production, limited capacity, and the commercial priorities of external suppliers often slow development, extend time to clinical use, and reduce the flexibility of development programs.
The GaiaCell CAR-T platform is designed as an integrated development framework that reduces dependence on external constraints and enables greater control over the entire pathway from development to clinical application.
The core objectives of the platform are:
GaiaCell develops and operates its own lentiviral vector and plasmid platform for CAR-T manufacturing. This enables greater predictability, improved control over availability, and reduced dependence on external suppliers of critical components. A development approach that eliminates the need for standard apheresis opens the possibility of a less invasive, logistically simpler, and potentially more widely accessible therapy.
CAR-T cells are delivered to the patient as a fresh product, without cryopreservation, which:
Our approach simultaneously addresses clinical requirements and industrial challenges related to the efficacy, accessibility, and manageability of CAR-T therapies. The combination of vector control, simplified cell preparation, and a fresh product enables:
As an initial clinical application, the platform is focused on CD19-targeted CAR-T therapy, a clinically established and globally validated indication. CD19 represents a deliberate entry point for implementing manufacturing workflows, quality systems, and clinical interfaces in an environment with well-defined clinical outcomes.
The platform is not limited to CD19. It is designed as a scalable CAR-T platform that enables further development and adaptation to additional targets and indications, in line with clinical needs and the strategic directions of collaborating partners.
The GaiaCell CAR-T program is developed within a clearly structured translational framework, with a focus on clinical feasibility and long-term usability. Details regarding targets, constructs, and manufacturing protocols remain part of a protected development environment and are subject to in-depth professional discussions within partnerships.
The GaiaCell CAR-T platform is designed for collaboration with:
We seek partnerships focused on co-development, clinical validation, and long-term value creation in the field of advanced cell therapies.